Cargando…

Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting

Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies, including tumor necrosis factor-α inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Saqa, Magan, Tejal, Vargas, Mario, Harrison, Abiola, Sofat, Nidhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207578/
https://www.ncbi.nlm.nih.gov/pubmed/25378947
http://dx.doi.org/10.2147/JPR.S69011
_version_ 1782340994752053248
author Ahmed, Saqa
Magan, Tejal
Vargas, Mario
Harrison, Abiola
Sofat, Nidhi
author_facet Ahmed, Saqa
Magan, Tejal
Vargas, Mario
Harrison, Abiola
Sofat, Nidhi
author_sort Ahmed, Saqa
collection PubMed
description Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies, including tumor necrosis factor-α inhibitors, often leads to suppression of disease activity observed at the clinical level. However, despite the era of widespread use of disease-modifying treatments, there remain significant groups of patients who continue to experience pain. Our study formulated a pain assessment tool in the arthritis clinic to assess feasibility of measurements including the visual analog scale (VAS) and painDETECT to assess multimodal features of pain in people with established RA (n=100). Clinical measures of disease activity (Disease Activity Score in 28 Joints [DAS28]) were also recorded. Our data showed that despite the majority of subjects on at least one disease-modifying agent, the majority of patients reported severe pain (54%) by VAS, despite well-controlled clinical disease, with mean DAS28 2.07±0.9. Using the painDETECT questionnaire, 67% of patients had unlikely neuropathic pain. A significant proportion of subjects (28%) had possible neuropathic pain and 5% had features of likely neuropathic pain by painDETECT scoring. We found a positive correlation between VAS and painDETECT (R(2)=0.757). Of note, the group who had likely or probable neuropathic pain also showed significantly increased pain reporting by VAS (P<0.01). Subjects who were clinically obese (body mass index >30) also had statistically higher proportions of pain reporting (VAS 89.0±0.7 mm) compared with subjects who had a normal body mass index (VAS 45.2±21.8 mm), P<0.05. Our findings suggest that multimodal features of pain perception exist in RA, including neuropathic and sensitization elements, perhaps explaining why a subgroup of people with RA continue to experience ongoing pain, despite their apparent suppression of inflammation.
format Online
Article
Text
id pubmed-4207578
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42075782014-11-06 Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting Ahmed, Saqa Magan, Tejal Vargas, Mario Harrison, Abiola Sofat, Nidhi J Pain Res Original Research Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies, including tumor necrosis factor-α inhibitors, often leads to suppression of disease activity observed at the clinical level. However, despite the era of widespread use of disease-modifying treatments, there remain significant groups of patients who continue to experience pain. Our study formulated a pain assessment tool in the arthritis clinic to assess feasibility of measurements including the visual analog scale (VAS) and painDETECT to assess multimodal features of pain in people with established RA (n=100). Clinical measures of disease activity (Disease Activity Score in 28 Joints [DAS28]) were also recorded. Our data showed that despite the majority of subjects on at least one disease-modifying agent, the majority of patients reported severe pain (54%) by VAS, despite well-controlled clinical disease, with mean DAS28 2.07±0.9. Using the painDETECT questionnaire, 67% of patients had unlikely neuropathic pain. A significant proportion of subjects (28%) had possible neuropathic pain and 5% had features of likely neuropathic pain by painDETECT scoring. We found a positive correlation between VAS and painDETECT (R(2)=0.757). Of note, the group who had likely or probable neuropathic pain also showed significantly increased pain reporting by VAS (P<0.01). Subjects who were clinically obese (body mass index >30) also had statistically higher proportions of pain reporting (VAS 89.0±0.7 mm) compared with subjects who had a normal body mass index (VAS 45.2±21.8 mm), P<0.05. Our findings suggest that multimodal features of pain perception exist in RA, including neuropathic and sensitization elements, perhaps explaining why a subgroup of people with RA continue to experience ongoing pain, despite their apparent suppression of inflammation. Dove Medical Press 2014-10-14 /pmc/articles/PMC4207578/ /pubmed/25378947 http://dx.doi.org/10.2147/JPR.S69011 Text en © 2014 Ahmed et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ahmed, Saqa
Magan, Tejal
Vargas, Mario
Harrison, Abiola
Sofat, Nidhi
Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
title Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
title_full Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
title_fullStr Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
title_full_unstemmed Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
title_short Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
title_sort use of the paindetect tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207578/
https://www.ncbi.nlm.nih.gov/pubmed/25378947
http://dx.doi.org/10.2147/JPR.S69011
work_keys_str_mv AT ahmedsaqa useofthepaindetecttoolinrheumatoidarthritissuggestsneuropathicandsensitizationcomponentsinpainreporting
AT magantejal useofthepaindetecttoolinrheumatoidarthritissuggestsneuropathicandsensitizationcomponentsinpainreporting
AT vargasmario useofthepaindetecttoolinrheumatoidarthritissuggestsneuropathicandsensitizationcomponentsinpainreporting
AT harrisonabiola useofthepaindetecttoolinrheumatoidarthritissuggestsneuropathicandsensitizationcomponentsinpainreporting
AT sofatnidhi useofthepaindetecttoolinrheumatoidarthritissuggestsneuropathicandsensitizationcomponentsinpainreporting